Outcome following local recurrence or in-transit metastases in cutaneous melanoma

Melanoma Research

Volumn 22, Issue 6, 2012, Pages 447-453

  Suojärvi, Nora J ^a   Jahkola, Tiina A ^a   Virolainen, Susanna ^a   Ilmonen, Suvi K ^a   Hernberg, Micaela M ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

in transit metastasis; local recurrence; melanoma; prognostic factors; survival

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; DACARBAZINE; LOMUSTINE; MELPHALAN; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CUTANEOUS MELANOMA; DISEASE CLASSIFICATION; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; IN-TRANSIT METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; SINGLE DRUG DOSE; TREATMENT OUTCOME; TUMOR VOLUME; ULCER;

ADULT; AGED; DISEASE-FREE SURVIVAL; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84869495451     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32835a310c     Document Type: Article

References (24)

1. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
2. Kettlewell S, Moyes C, Bray C, Soutar D, MacKay A, Byrne D, et al. Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. BMJ 2006; 332:1423.
3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-206.
4. Stucky CC, Gray RJ, Dueck AC,Wasif N, Laman SD, Sekulic A, et al. Risk factors associated with local and in-transit recurrence of cutaneous melanoma. Am J Surg 2010; 200:770-775.
5. Soong SJ, Harrison RA, McCarthy WH, Urist MM, Balch CM. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 1998; 67:228-233.
6. Meier F,Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147:62-70.
7. Grunhagen DJ, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb perfusion for melanoma patients-a review of its indications and the role of tumor necrosis factor-alpha. Eur J Surg Oncol 2006; 32:371-380.
8. Kandamany N, Mahaffey P. Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases. Lasers Med Sci 2009; 24:411-414.
9. Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996; 3:446-452.
10. Francken AB, Accortt NA, Shaw HM, Wiener M, Soong SJ, Hoekstra HJ, et al. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 2008; 15:1476-1484.
11. Ilmonen S, Asko-Seljavaara S, Kariniemi AL, Jeskanen L, Pyrhonen S, Muhonen T. Prognosis of primary melanoma. Scand J Surg 2002; 91:166-171.
12. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, Ringborg U. Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol 1999; 38:549-557.
13. Brauer JA, Wriston CC, Troxel AB, Elenitsas R, Shin DB, Guerry D, et al. Characteristics associated with early and late melanoma metastases. Cancer 2010; 116:415-423.
14. Kimsey TF, Cohen T, Patel A, Busam KJ, Brady MS. Microscopic satellitosis in patients with primary cutaneous melanoma: implications for nodal basin staging. Ann Surg Oncol 2009; 16:1176-1183.
15. Pawlik TM, Ross MI, Johnson MM, Schacherer CW, McClain DM, Mansfield PF, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005; 12:587-596.
16. Chao C, Wong SL, Ross MI, Reintgen DS, Noyes RD, Cerrito PB, et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg 2002; 184:520-524.
17. Pawlik TM, Ross MI, Thompson JF, Eggermont AMM, Gerchenwald JE. Low risk of in-transit metastasis in patients with cutaneous melanoma undergoing sentinel lymph node biopsy. J Clin Oncol 2005; 23:4588-4590.
18. Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg 2003; 46:419-426.
19. Lens MB, Nathan P, Bataille V. Excision margins for primary cutaneous melanoma: updated pooled analysis of randomized controlled trials. Arch Surg 2007; 142:885-891.
20. Sladden MJ, Balch C, Barzilai DA, Berg D, Freiman A, Handiside T, et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev 2009; 4:CD004835.
21. Tanabe KK, Reintgen DS, Balch CM. Local recurrence of melanoma and their management. In: Balch CM, Houghton AN, Sober AJ, Soong S, Atkins MB, Thompson JF, editors. Cutaneous melanoma. 5th ed. St Louis, Missouri, USA: Quality Medical Publishing Inc.; 2009. pp. 323-335.
22. Meyers MO, Yeh JJ, Frank J, Long P, Deal AM, Amos KD, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol 2009; 16:941-947.
23. Kruijff S, Bastiaannet E, Suurmeijer AJH, Hoekstra HJ. Detection of melanoma nodal metastases; differences in detection between elderly and younger patients do not affect survival. Ann Surg Oncol 2010; 17:3008-3014.
24. Francken AB, Accortt NA, Shaw HM, Colman MH, Wiener M, Soong SJ, et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg 2008; 95:1401-1407